SecBot SecBot

VTRS drug pipeline

Viatris Inc · 3 rated drugs
$20.49
−1.2% 1-day · Nov 17
Next catalyst
Dec 27, 2026
MR-107A-02 (fast-acting meloxicam) PDUFA date · in 40 days
Typical move on FDA news
±2.7%
1-day, median of 21 events
IV rank
37
IV 38% · HV 30%
Rated drugs
3
3 neutral
Phase 3 trials
16
7 with results posted

Upcoming catalysts

2 dated
  1. Dec 27, 202640d
    MR-107A-02 (fast-acting meloxicam)
    PDUFA date · moderate-to-severe acute pain
  2. Dec 31, 2026
    Cenerimod
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseFiled/PDUFA
Time to marketApproved product (Xulane) already on market since 2014. XULANE LO (low-dose version) PDUFA decision July 30, 2026 — potential launch H2 2026 if approved.

norelgestromin/ethinyl estradiol weekly patch norelgestromin/ethinyl estradiol Updated Jun 30

What to watch

Watch the July 30, 2026 PDUFA date for XULANE LO. If approved, the low-estrogen positioning and "best-in-class adhesion" claims could help Viatris capture share in the ~$1B+ contraceptive patch market. A CRL (complete response letter) would be a near-term negative but not company-threatening given Viatris's diversified portfolio. The stock is near its 52-week high (~$17.53) with 12 sell-side analysts averaging a $17.81 target, suggesting modest upside is already priced in.

Bull case
  • Positive Phase 3 data (NCT05139121) showed XULANE LO met primary and all secondary efficacy and safety endpoints with a Pearl Index of 4.14 and 3.7% cumulative pregnancy probability (source: newsroom.viatris.com/2025-05-08).
  • The lower estrogen dose (17.5 mcg vs 35 mcg) directly addresses the cardiovascular black-box warning on the original Xulane, potentially expanding the addressable patient population and differentiating from Twirla (source: ctiexchange.org/cti-tracker/xulane-lo).
  • Viatris showcased strong adhesion data at ACOG 2026, claiming potential 'best-in-class' patch performance, a key driver of real-world compliance (source: patientcareonline.com/view/mr-100a-01-weekly-contraceptive-patch-data-presented-at-acog-2026).
Bear case
  • Viatris is a large, diversified pharma ($3.5B quarterly revenue), XULANE LO approval would be a nice growth contributor but not a needle-mover for the overall stock (source: seekingalpha.com and fool.com earnings transcripts).
  • The contraceptive patch faces intense competition not just from Twirla (the other branded weekly patch) but also from oral contraceptives, IUDs, implants, rings, and long-acting injectables, patches remain a small slice of contraception (source: drugpatentwatch.com/p/drug-price/drugname/TWIRLA).
  • Despite positive Phase 3 data, the Pearson Index of 4.14 means ~4 pregnancies per 100 woman-years, slightly higher than some other methods, which may limit uptake (source: newsroom.viatris.com).
● neutral
Impact
PhaseFiled/sNDA under FDA review (Phase 3 completed)
Time to marketIf approved at the October 17, 2026 PDUFA date, commercial launch could follow within weeks (Ryzumvi is already manufactured and marketed for its approved indication).

MR-141 (phentolamine ophthalmic solution 0.75%) phentolamine ophthalmic solution Updated Jun 30

What to watch

Watch for the October 17, 2026 PDUFA decision on MR-141's presbyopia label expansion. Approval would add a differentiated non-pilocarpine presbyopia drop to Viatris's portfolio but faces crowded competition (Vuity, Qlosi, newly-approved Yuvezzi). For VTRS, this is a single positive catalyst in a broader turnaround story, not a stock-defining binary. The stock already rallied ~11% in 5 days on the sNDA acceptance news in Feb 2026.

Bull case
  • Differentiated mechanism, phentolamine is an alpha-blocker that constricts the pupil via the iris dilator muscle, distinct from pilocarpine-based competitors (Vuity, Qlosi) that act on the sphincter muscle, potentially offering a different side-effect profile with less brow ache/dim vision.
  • Both pivotal Phase 3 trials (VEGA-2 and VEGA-3) met primary and all secondary endpoints, showing statistically significant improvement in near vision without compromising distance vision or causing serious treatment-related adverse events.
  • PDUFA date of October 17, 2026 is imminent (~3.5 months away), and as a sNDA for an already-approved drug with established safety, the probability of approval is reasonably high.
Bear case
  • Crowded competitive landscape, Vuity (AbbVie/Allergan) is the established market leader since 2021, Qlosi (Orasis) launched April 2025, and Yuvezzi (Tenpoint Therapeutics) was just FDA-approved in January 2026 as the first dual-agent presbyopia drop. MR-141 would be entering a market with multiple entrenched and new competitors.
  • Viatris is a large, diversified pharma company ($14.3B revenue, ~$18-19B market cap). Even a successful presbyopia launch would be incremental, unlikely to move the stock more than a few percent. The drug is not a make-or-break value driver.
  • Ryzumvi's current approved indication (reversing pupil dilation) is a niche market with modest sales, so there is no large existing revenue base to leverage. The presbyopia opportunity requires a new commercial build-out in an increasingly competitive space.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized since October 2021.

Tyrvaya varenicline solution Updated Nov 9

What to watch

Tyrvaya is now owned by Harrow (HROW), not Viatris (VTRS). The next catalyst is Harrow's commercial execution: Tyrvaya closed on October 5, 2026, so its contribution to Harrow's Q4 2026 and full-year 2027 results will be the key metric to watch. Harrow expects Tyrvaya to add more than $30M in 2027 revenue. For Viatris, Tyrvaya is a divested non-core asset with no further impact.

Bull case
  • Tyrvaya is the first and only FDA-approved nasal spray for dry eye disease, a novel and differentiated delivery mechanism that avoids eye-drop application and may appeal to patients with tolerability issues with topical drops.
  • Harrow expects Tyrvaya to add more than $30M in 2027 revenue, and the company reported record Q3 2026 revenue of $99.3M, demonstrating strong commercial momentum across its portfolio.
  • Analyst consensus on Harrow (HROW) is Strong Buy, with a mean price target of $63 (134% implied upside from the $26.89 close), reflecting optimism about the Tyrvaya acquisition and broader product lineup.
Bear case
  • Tyrvaya faces entrenched competition from established dry-eye therapies including Restasis (cyclosporine), Xiidra (lifitegrast), Cequa, and numerous artificial tear products, all of which are eye drops that may be more familiar to patients and prescribers.
  • Harrow paid up to $100M ($30M upfront plus up to $70M in sales milestones), creating financial pressure to grow the brand quickly; if Tyrvaya sales underwhelm, Harrow may not achieve the milestone revenue targets.
  • As a nasal spray for an eye condition, Tyrvaya has a novel delivery mechanism that may face adoption resistance from patients and eye-care professionals accustomed to topical drops.

Other drugs in filings and trials

no drug report yet
  • MR-107A-02 (fast-acting meloxicam) Next: PDUFA date · Dec 27, 2026 Last: NDA filed · May 31, 2026
  • low-dose estrogen weekly patch Last: PDUFA decision · Jul 30, 2026
  • octreotide acetate for injectable suspension Last: Approval · Dec 1, 2025
  • ERMEZA Last: Approval · Apr 29, 2022
  • SEMGLEE Last: Approval · Jul 28, 2021
  • HULIO Last: Approval · Jul 6, 2020
  • PRETOMANID Last: Approval · Aug 14, 2019
  • YUPELRI Last: Approval · Nov 9, 2018
  • VANCOMYCIN HYDROCHLORIDE Last: Approval · Jul 10, 2018
  • FULPHILA Last: Approval · Jun 4, 2018
  • SYMFI Last: Approval · Mar 22, 2018
  • CIMDUO Last: Approval · Feb 28, 2018
  • SYMFI LO Last: Approval · Feb 5, 2018
  • OGIVRI Last: Approval · Dec 1, 2017
  • TOBI PODHALER Last: Approval · Mar 22, 2013
  • REVATIO Last: Approval · Aug 30, 2012
  • DYMISTA Last: Approval · May 1, 2012
  • Allopurinol 1 trial
  • Allopurinol Tablet 1 trial
  • Atorvastatin 2 trials
  • CAM2029 (octreotide subcutaneous depot) 1 trial
  • Cenerimod 1 trial
  • Dexmedetomidine 1 trial
  • Eszopiclone 1 trial
  • Fluvoxamine 1 trial
  • Inhaled budesonide and formoterol 1 trial
  • Lenalidomide 10 mg 1 trial
  • Midodrine 1 trial
  • Mirtazapine 1 trial
  • Paclitaxel 1 trial
  • Pomalidomide 1 trial
  • prazosin hydrochloride 1 trial
  • Sorafenib 1 trial
  • Sucralfate 1 trial
  • Tamoxifen 10 mg Tablet 1 trial
  • Ticagrelor 90mg 2 trials
  • Use of Linaclotide as a single agent Colonoscopy prep 1 trial
  • Vancomycin 1 trial
  • Varenicline 1 trial

Past FDA events & how the stock moved

21 events
DateDrugEvent1 day5 days
Oct 17, 2026MR-141 (phentolamine ophthalmic solution 0.75%)PDUFA decision−2.1%−3.5%
Jul 30, 2026low-dose estrogen weekly patchPDUFA decision−1.5%−8.6%
May 31, 2026MR-107A-02NDA filed−2.8%−2.3%
Feb 1, 2026MR-141 (phentolamine ophthalmic solution 0.75%)NDA filed+4.5%+11.4%
Dec 1, 2025octreotide acetate for injectable suspensionApproval+0.2%+3.7%
Dec 1, 2025low-dose estrogen weekly patchNDA filed+0.2%+3.7%
Apr 29, 2022ERMEZAApproval−2.7%−5.2%
Jul 28, 2021SEMGLEEApproval+2.7%−1.1%
Jul 6, 2020HULIOApproval+1.1%+1.3%
Jun 11, 2020SEMGLEEApproval−8.0%−5.7%
Aug 14, 2019PRETOMANIDApproval−10.7%−3.2%
Nov 9, 2018YUPELRIApproval−3.3%−6.0%
Jul 10, 2018VANCOMYCIN HYDROCHLORIDEApproval−2.6%−2.0%
Jun 4, 2018FULPHILAApproval+2.9%+7.5%
Mar 22, 2018SYMFIApproval−5.6%+0.0%
Feb 28, 2018CIMDUOApproval−1.0%+3.4%
Feb 5, 2018SYMFI LOApproval−2.7%−3.6%
Dec 1, 2017OGIVRIApproval+2.5%+5.9%
Mar 22, 2013TOBI PODHALERApproval−3.0%−4.9%
Aug 30, 2012REVATIOApproval−0.2%+1.9%
May 1, 2012DYMISTAApproval−1.2%−3.2%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
CenerimodA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusPhase 3Active not recruiting451Dec 31, 2026
SucralfateReducing Acute Upper Gastrointestinal Side-Effects of Thoracic IrradiationPhase 2Completed142Aug 26, 2026
VareniclineOff-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2Phase 2Terminated3Aug 5, 2026
Everolimus 0.5 MG once per dayEverolimus Aging StudyPhase 2Completed106Jun 30, 2026
AllopurinolAllopurinol Improves Heart Function in African Americans With Resistant HypertensionPhase 2Completed40Apr 30, 2026
Use of Linaclotide as a single agent Colonoscopy prepLinaclotide for Colonoscopy Bowel PrepPhase 2Terminated4Apr 7, 2026
RoflumilastRoflumilast or Azithromycin to Prevent COPD Exacerbations TrialPhase 3Completed1,032Mar 1, 2026
EszopicloneDo Endotypes Predict Response and Sequelae in OSA PatientsPhase 2Completed233Feb 11, 2026
PaclitaxelCoenzyme Q10 for Neuroprotection in Paclitaxel-Induced NeuropathyPhase 2Completed50Feb 10, 2026
VareniclineTobacco Treatment Optimization and Preferences During Concurrent Cancer TreatmentPhase 2Completed126Jan 2, 2026
Tamoxifen 10 mg TabletLow Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTionPhase 2Completed110Dec 31, 2025
Febuxostat TabletsComparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic PatientsPhase 2Completed60Dec 30, 2025
MidodrineAutomated Abdominal Binder for Orthostatic HypotensionPhase 2Completed28Nov 19, 2025
MirtazapineTrial of Mirtazapine for Depression in IBDPhase 2Completed76Oct 3, 2025
MesalamineFenofibrate in Ulcerative ColitisPhase 3Completed60Sep 20, 2025
Inhaled budesonide and formoterolARrest RESpiraTory Failure From PNEUMONIAPhase 3Terminated · results465Jul 22, 2025
Ticagrelor 90mgTicagrelor Monotherapy After StentingPhase 2Completed200Jun 26, 2025
Lenalidomide 10 mgMCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsPhase 2Completed15May 31, 2025
DexmedetomidineDexmedetomidine in Postoperative AnalgesiaPhase 3Completed100May 15, 2025
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TCPharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated TuberculosisPhase 2Completed · results30May 7, 2025
VareniclineCombining Varenicline and Guanfacine for Smoking CessationPhase 2Completed · results167Apr 30, 2025
FluvoxamineFluvoxamine for Long COVID-19Phase 3Completed · results191Mar 15, 2025
VancomycinVancomycin for Primary Sclerosing CholangitisPhase 3Terminated · results102Mar 3, 2025
DexmedetomidineDexmedetomidinine in the Prevention of Postoperative Delirium in the Intensive Care Unit After Cardiac SurgeryPhase 3Completed300Feb 1, 2025
norelgestromin/ethinyl estradiol weekly patchStudy of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesPhase 3Completed · results1,320Jan 15, 2025
Revefenacin Inhalation Solution [Yupelri]Revefenacin in Acute Respiratory Insufficiency in COPDPhase 2Completed · results21Jan 1, 2025
dolutegravirANRS 12372 MODERATO StudyPhase 3Completed480Dec 30, 2024
MesalamineClinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative ColitisPhase 3Completed50Dec 20, 2024
PomalidomidePomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionPhase 2Completed · results26Nov 29, 2024
AtorvastatinThe Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer PatientsPhase 2Completed44Oct 20, 2024
LenalidomideUpfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaPhase 2Completed · results40Aug 22, 2024
SorafenibEvaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCPhase 3Completed326May 31, 2024
MesalamineRepurposing Fenofibrate in Modulating AMPK/NLRP3 Inflammasome in Patients With Ulcerative ColitisPhase 2Completed70Apr 20, 2024
Allopurinol TabletAllopurinol and Pathogenesis of CirrhosisPhase 2Completed110Mar 1, 2024
Atorvastatin 80mgAtorvastatin in Patients With Ulcerative ColitisPhase 2Completed50Mar 1, 2024
roflumilast cream 0.3%Bioequivalence Study of Two Treatments for the Treatment of Plaque PsoriasisPhase 3Completed · results416Aug 8, 2023
TicagrelorThe Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary InterventionPhase 3Completed40Jul 6, 2023
prazosin hydrochlorideChronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of PrazosinPhase 2Completed · results89May 31, 2023
CAM2029 (octreotide subcutaneous depot)A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyPhase 3Completed · results72May 2, 2023
Ticagrelor 90mgThe Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular InterventionsPhase 3Terminated · results31Mar 28, 2023